Reduction in hemolysis after eculizumab. Treatment with eculizumab induced rapid and consistent inhibition of hemolysis to near normal levels in all patients after 36 months of follow-up. Patients with both PNH/AA and classic PNH had significant median change of LDH level.
Abbreviations: AA, aplastic anemia; ecu, eculizumab; PNH, paroxysmal nocturnal hemoglobinuria; ULN, upper limit of normal.